Quanterix Releases Financial Results for the Fourth Quarter of 2024

About this update from Quanterix Corporation

[{"type":"text","content":"Delivers seventh consecutive quarter of double-digit revenue growth","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"BILLERICA, Mass., March 17, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024.","length":254,"tagName":"p"},{"type":"text","content":""During the fourth quarter, we delivered 11% revenue growth, our seventh straight quarter of double-digit growth, despite a capital constrained environment," said Masoud Toloue, Chief Executive Officer of Quanterix. "Our ability to grow in a difficult environment is the result of investments in our business model, which focuses on key vertical markets and recurring revenues. We are expanding our approach to immunology and oncology, which will materially grow our addressable market, increase leverage and scale. Our announced acquisition of Akoya Biosciences is an important step forward in the execution of this strategy."","length":647,"tagName":"p"},{"type":"text","content":"On January 10, 2025, Quanterix announced a definitive merger agreement to acquire Akoya in an all-stock transaction. The proposed combination will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, uniquely positioning the company to accelerate market development of new clinical tests. The transaction is expected to close in the second quarter of 2025, subject to certain closing conditions including approval by both companies’ shareholders.","length":507,"tagName":"p"},{"type":"text","content":"Fourth Quarter Financial Highlights","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $35.2 million, an increase of 11% compared to $31.5 million in the prior year.","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":89,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"GAAP gross margin of 63.0%, as compared to 61.5% in the prior year. Adjusted gross margin (non-GAAP) of 57.7% as compared to 54.7% in the prior year.","length":149,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":149,"olType":false},{"type":"list","items":...

More updates from Quanterix Corporation